| 多重耐药鲍曼不动杆菌治疗药物的研究进展 |
| |
| 引用本文： | 张晓玲[综述],于翠香[审校]. 多重耐药鲍曼不动杆菌治疗药物的研究进展[J]. 医学综述, 2013, 0(21): 3968-3970 |
| |
| 作者姓名： | 张晓玲[综述] 于翠香[审校] |
| |
| 作者单位： | [1]山东省医学科学院,济南250014 [2]山东省千佛山医院呼吸科,济南250014 |
| |
| 摘 要： | 随着广谱抗菌药物的广泛应用，多重耐药鲍曼不动杆菌不断出现，并已成为现代医疗体系的重大挑战。碳青霉烯类抗生素是治疗鲍曼不动杆菌感染最有效的药物之一。但碳青霉烯类耐药鲍曼不动杆菌也逐渐增多，使治疗药物的选择非常局限。联合用药在体外研究中显示出不同程度的协同作用，新型药物的开发也显得格外重要。
|
| 关 键 词： | 多重耐药鲍曼不动杆菌 单药治疗 联合用药 新型药物 |
The Research Progress of Medication Treatment of Multidrug-resistant Acinetobacter Baumannii |
| |
| Affiliation: | ZHANG Xiao-ling, YU Cui-xiang. ( 1. Shandong Academy of Medical Science, Jinan 250014, China; 2. Department of Respiratory Medicine, Shandong Provincial Qianfoshan Hospital ,Jinan 250014, China) |
| |
| Abstract: | With the wide use of broad-spectrum antimicrobial agents, muhidrug-resistant acinetobacter baumannii appear constantly and the infection due to it become a significant challenge to modem heahhcare system. Carbapenem is one of the most effective drugs. However, carbapenem-resistant strains have now emerged around the world, which made the treatment options very limited. Combination therapy in vitro studies show different synergistic activities ,while probing for new agent is also very important. |
| |
| Keywords: | Muhidrug-resistant acinetobacter baumannii Monotherapy Drug combination New agents |
| 本文献已被 维普 等数据库收录！ |
